IDEXX Story

<div class='circular--portrait' style='background:#8B008B;color: #ffffff;font-size:4em;'>IL</div>
IDXX -- USA Stock  

USD 377.83  8.54  2.21%

IDEXX Laboratories Cash and Equivalents Turnover is fairly stable at the moment as compared to the past year. IDEXX Laboratories reported Cash and Equivalents Turnover of 22.48 in 2019. Cash Flow Per Share is likely to grow to 5.80 in 2020, whereas Net Income Per Employee is likely to drop slightly above 38.8 K in 2020. As many of us are excited about healthcare space, it is fair to break down IDEXX Laboratories. I will take a closer look at this stock and the current sentiment generated by investors. In this post, I will also go over some essential variables affecting IDEXX Laboratories' products, and show how it may impact IDEXX Laboratories outlook for active traders this year.
Published over a month ago
View all stories for IDEXX Laboratories | View All Stories
IDEXX Laboratories (NASDAQ:IDXX) continues to rise
On a scale of 0 to 100, IDEXX Laboratories holds a performance score of 19. The company retains a Market Volatility (i.e. Beta) of 0.5926, which attests to possible diversification benefits within a given portfolio. Let's try to break down what IDEXX's beta means in this case. As returns on the market increase, IDEXX Laboratories returns are expected to increase less than the market. However, during the bear market, the loss on holding IDEXX Laboratories will be expected to be smaller as well. Although it is vital to follow IDEXX Laboratories current price history, it is good to be conservative about what you can do with the information regarding equity current price movements. The approach into determining future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. We have found twenty-one technical indicators for IDEXX Laboratories, which you can use to evaluate the performance of the firm. Please utilizes IDEXX Laboratories mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to make a quick decision on whether IDEXX Laboratories current trending patterns will revert.

How important is IDEXX Laboratories's Liquidity

IDEXX Laboratories financial leverage refers to using borrowed capital as a funding source to finance IDEXX Laboratories ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. IDEXX Laboratories financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between IDEXX Laboratories's total debt and its cash.

How IDEXX utilizes its cash?

To perform a cash flow analysis of IDEXX Laboratories, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash IDEXX Laboratories is receiving and how much cash it distributes out in a given period. The IDEXX Laboratories cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. IDEXX Laboratories Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. IDEXX Laboratories reported Net Cash Flow from Operations of 459.16 Million in 2019

What did IDEXX Laboratories file with SEC?

The SEC filings are financial statements or other formal documents of IDEXX Laboratories that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database. Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to IDEXX shareholders may or may not be submitted as SEC does not always require it.
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
Submission of Matters to a Vote of Security Holders
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to IDEXX shareholders may or may not be submitted as SEC does not always require it.

IDEXX Laboratories exotic insider transaction detected

Legal trades by IDEXX Laboratories insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
IDEXX insider trading alert for general transaction of common stock by Jonathan Ayers, the corporate stakeholder, on 6th of September 2020. This event was filed by Idexx Laboratories Inc with SEC on 2020-08-28. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Details

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. IDEXX Laboratories has an asset utilization ratio of 166.78 percent. This suggests that the company is making $1.67 for each dollar of assets. An increasing asset utilization means that IDEXX Laboratories is more efficient with each dollar of assets it utilizes for everyday operations.
 2019 2020 (projected)
Long Term Debt to Equity3.543.82
Interest Coverage18.0518.53

Our take on today IDEXX Laboratories rise

IDEXX Laboratories current kurtosis rises over 2.12. IDEXX Laboratories currently demonstrates below-verage downside deviation. It has Information Ratio of 0.22 and Jensen Alpha of 0.52. However, we do advice investors to further question IDEXX Laboratories expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk.

Our Final Take On IDEXX Laboratories

While many other companies within the diagnostics & research industry are still a little expensive, even after the recent corrections, IDEXX Laboratories may offer a potential longer-term growth to investors. While some investors may not share our view, we believe that right now is not a good time to increase your holdings in IDEXX. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to IDEXX Laboratories.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of IDEXX Laboratories. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com